Clinical Trials
8
Active:1
Completed:6
Trial Phases
2 Phases
Phase 1:1
Phase 2:7
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 2
7 (87.5%)Phase 1
1 (12.5%)Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Aptinyx
- Target Recruit Count
- 121
- Registration Number
- NCT05181995
- Locations
- 🇺🇸
Aptinyx Clinical Site, Plano, Texas, United States
NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking)
Phase 2
Active, not recruiting
- Conditions
- Mild Cognitive ImpairmentParkinson DiseaseMild DementiaLewy Body Disease
- Interventions
- Drug: Placebo Oral Capsule
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Aptinyx
- Target Recruit Count
- 99
- Registration Number
- NCT04148391
- Locations
- 🇺🇸
Aptinyx Clinical Site, Spokane, Washington, United States
Efficacy and Safety of NYX-2925 in Subjects With Fibromyalgia
- First Posted Date
- 2019-11-01
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Aptinyx
- Target Recruit Count
- 310
- Registration Number
- NCT04147858
- Locations
- 🇺🇸
Aptinyx Clinical Site, Bellevue, Washington, United States
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)
Phase 2
Completed
- Conditions
- Diabetic Peripheral Neuropathic Pain
- Interventions
- Drug: NYX-2925 50 mgDrug: Placebo
- First Posted Date
- 2019-10-31
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Aptinyx
- Target Recruit Count
- 228
- Registration Number
- NCT04146896
- Locations
- 🇺🇸
Aptinyx Clinical Site, San Antonio, Texas, United States
Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder
Phase 2
Completed
- Conditions
- Post-Traumatic Stress Disorder
- Interventions
- Drug: Placebo oral capsule
- First Posted Date
- 2019-08-05
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Aptinyx
- Target Recruit Count
- 160
- Registration Number
- NCT04044664
- Locations
- 🇺🇸
Aptinyx Clinical Site, Bellevue, Washington, United States
🇺🇸Aptinyx, Atlanta, Georgia, United States
- Prev
- 1
- 2
- Next
News
No news found